<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04847947</url>
  </required_header>
  <id_info>
    <org_study_id>72/UN2.F1/ETIK/PPM.00.02/2021</org_study_id>
    <nct_id>NCT04847947</nct_id>
  </id_info>
  <brief_title>The Effect of Cholecalciferol in Pre-frail Elderly</brief_title>
  <official_title>The Effect of Cholecalciferol on Frailty Syndrome in Pre-frail Elderly Receiving Calcium Supplementation : A Study on Handgrip Strength, Gait Speed, Vitamin D Receptor, Insulin Growth Factor-1 and Interleukin-6</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indonesia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indonesia University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D plays important role in musculoskeletal health and has been known to influence&#xD;
      immune system. Inflammaging is one of risk factors that may contribute to development of&#xD;
      frailty in elderly.&#xD;
&#xD;
      The purpose of this study is to determine the effects of cholecalciferol in pre-frail elderly&#xD;
      receiving calcium supplementation on handgrip strength, gait speed, vitamin D receptor, IGF-1&#xD;
      and IL-6. Fall incidence and improvement of frailty status will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double-blind placebo-controlled study in pre-frail elderly. Measurement&#xD;
      of frailty status based on Fried frailty phenotype criteria (weight loss, weakness,&#xD;
      exhaustion, slowness, low physical activity level) .&#xD;
&#xD;
      Subjects who fulfill eligibility criteria will be randomized into 2 groups, one group will&#xD;
      received cholecalciferol 4000 IU once daily and the other group will received placebo once&#xD;
      daily. Each subjects in both groups will received calcium lactate 500 mg once daily.&#xD;
      Intervention will be held for 12 weeks.&#xD;
&#xD;
      Handgrip strength and gait speed will be assessed at baseline, every 4 weeks, and at week 12.&#xD;
      Other outcome measures will be assessed at baseline and at week 12.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Handgrip strength</measure>
    <time_frame>12 weeks (evaluation every 4 weeks)</time_frame>
    <description>Change from baseline in handgrip strength. Measurement: handgrip dynamometer (Jamar Hydraulic Hand Dynamometer )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gait speed</measure>
    <time_frame>12 weeks (evaluation every 4 weeks)</time_frame>
    <description>Change from baseline in gait speed. Measurement: 15-feet walking test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vitamin D receptor (VDR) monocyte level</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in VDR monocyte level. Measurement : flowcytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukine 6 (IL-6) monocyte level</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in IL-6 monocyte level. Measurement : flowcytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Growth Factor-1 (IGF-1) monocyte level</measure>
    <time_frame>12 weeks</time_frame>
    <description>Change from baseline in IGF-1 monocyte level. Measurement : flowcytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum VDR level</measure>
    <time_frame>12 weeks</time_frame>
    <description>change from baseline in serum VDR level. Measurement : ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IGF-1 level</measure>
    <time_frame>12 weeks</time_frame>
    <description>change from baseline in serum IGF-1 level. Measurement : ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum IL-6 level</measure>
    <time_frame>12 weeks</time_frame>
    <description>change from baseline in serum IL-6 level. Measurement : ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fall incidence</measure>
    <time_frame>12 weeks</time_frame>
    <description>number of fall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frailty status</measure>
    <time_frame>12 weeks</time_frame>
    <description>improvement in frailty status</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Pre-frail Elderly</condition>
  <arm_group>
    <arm_group_label>Interventional group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral capsule Placebo once daily and Calcium Lactate 500 mg once daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Oral capsule Cholecalciferol 4000 IU once daily and Calcium Lactate 500 mg once daily for 12 weeks</description>
    <arm_group_label>Interventional group</arm_group_label>
    <other_name>Vitamin D3</other_name>
    <other_name>Prove D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral capsule Placebo containing white rice flour in the same identical looking with active drug once daily and Calcium Lactate 500 mg once daily for 12 weeks</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pre-frail elderly&#xD;
&#xD;
          2. Capable to understand and carry-out the instruction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to cholecalciferol, calcium, or its components&#xD;
&#xD;
          2. Hypercalcemia (total serum calcium &gt; 10,5 mg/dL)&#xD;
&#xD;
          3. Unwilling to stop using drug contain vitamin D or vitamin D analog or calcium&#xD;
&#xD;
          4. Using steroid or NSAID routinely&#xD;
&#xD;
          5. Acute illness during inclusion period, eg. pneumonia, stroke attack, acute&#xD;
             exacerbation of chronic obstructive pulmonary disease, asthma attack, hypertensive&#xD;
             urgency/emergency, acute decompensated heart failure&#xD;
&#xD;
          6. Having condition that can affect measurement of handgrip strength and gait speed, eg.&#xD;
             hemiparesis, severe pain in extremities&#xD;
&#xD;
          7. Hepatic cirrhosis, malignancy, autoimmune disease, nephrolithiasis, malabsorption&#xD;
             syndrome (eg. chronic diarrhea) , diabetes mellitus with HbA1c &gt; = 8% in the last 3&#xD;
             months, diabetes mellitus with obvious sign and symptoms of catabolic decompensation&#xD;
             (polyphagia, polydipsia, polyuria), chronic kidney disease stage IV-V or decreased&#xD;
             renal function with estimated glomerular filtration rate &lt; 30 ml/minute/1,73 m2&#xD;
&#xD;
          8. Using drug that can affect vitamin D absorption, eg. bile acid sequestrants&#xD;
&#xD;
          9. Cognitive impairment (Abbreviated Mental Test score &lt; 8)&#xD;
&#xD;
         10. Depression (Geriatric Depression Scale score &gt; = 10)&#xD;
&#xD;
         11. Unwilling to join the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noto Dwimartutie, MD, SpPD-KGer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Geriatric, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Noto Dwimartutie, MD, SpPD-KGer</last_name>
    <phone>+62 21 31900275</phone>
    <email>n_dwimartutie@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cipto Mangunkusumo General Hospital</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <zip>10430</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Setiati S, Anugrahini, Fransiska JE, Tamin TZ, Istanti R. Combination of alfacalcidol and calcium improved handgrip strength and mobility among Indonesian older women: A randomized controlled trial. Geriatr Gerontol Int. 2018 Mar;18(3):434-440. doi: 10.1111/ggi.13201. Epub 2017 Nov 15.</citation>
    <PMID>29143428</PMID>
  </reference>
  <reference>
    <citation>Bray NW, Doherty TJ, Montero-Odasso M. The Effect of High Dose Vitamin D3 on Physical Performance in Frail Older Adults. A Feasibility Study. J Frailty Aging. 2018;7(3):155-161. doi: 10.14283/jfa.2018.18.</citation>
    <PMID>30095145</PMID>
  </reference>
  <reference>
    <citation>Meireles MS, Kamimura MA, Dalboni MA, Giffoni de Carvalho JT, Aoike DT, Cuppari L. Effect of cholecalciferol on vitamin D-regulatory proteins in monocytes and on inflammatory markers in dialysis patients: A randomized controlled trial. Clin Nutr. 2016 Dec;35(6):1251-1258. doi: 10.1016/j.clnu.2016.04.014. Epub 2016 Apr 26.</citation>
    <PMID>27161894</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indonesia University</investigator_affiliation>
    <investigator_full_name>dr. Noto Dwimartutie</investigator_full_name>
    <investigator_title>, SpPD-KGer</investigator_title>
  </responsible_party>
  <keyword>Frailty</keyword>
  <keyword>Pre-frail</keyword>
  <keyword>Elderly</keyword>
  <keyword>Cholecalciferol</keyword>
  <keyword>Handgrip strength</keyword>
  <keyword>Gait speed</keyword>
  <keyword>Vitamin D receptor</keyword>
  <keyword>Insulin Growth Factor-1</keyword>
  <keyword>Interleukin-6</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

